Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?

Movement disorders : official journal of the Movement Disorder Society - 1 Nov 2022

Zimprich Alexander

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Share to Mutation
Share to Parkinson Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36196588
DOI: 10.1002/mds.29243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?PMID 36196588Read ↗

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read ↗

LRRK2 and Proteostasis in Parkinson's Disease.Semantic proximity Read ↗

Recent advances in targeting LRRK2 for Parkinson's disease treatment.Semantic proximity Read ↗

LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting.Semantic proximity Read ↗

LRRK2 inhibitor progresses for Parkinson disease.Semantic proximity Read ↗

Targeting LRRK2 in Parkinson's disease: an update on recent developments.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

Role of LRRK2 in physiological activities, diseases, and therapy.Semantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.